1. Home
  2. DX vs SUPN Comparison

DX vs SUPN Comparison

Compare DX & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dynex Capital Inc.

DX

Dynex Capital Inc.

HOLD

Current Price

$12.61

Market Cap

2.8B

Sector

Real Estate

ML Signal

HOLD

Logo Supernus Pharmaceuticals Inc.

SUPN

Supernus Pharmaceuticals Inc.

HOLD

Current Price

$46.34

Market Cap

2.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DX
SUPN
Founded
1987
2005
Country
United States
United States
Employees
28
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
2.8B
IPO Year
N/A
2010

Fundamental Metrics

Financial Performance
Metric
DX
SUPN
Price
$12.61
$46.34
Analyst Decision
Buy
Strong Buy
Analyst Count
3
5
Target Price
$14.75
$61.60
AVG Volume (30 Days)
6.2M
854.3K
Earning Date
04-20-2026
05-05-2026
Dividend Yield
15.11%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$392,755,000.00
Revenue This Year
N/A
$22.70
Revenue Next Year
N/A
$19.14
P/E Ratio
$5.66
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.83
$32.83
52 Week High
$14.93
$59.68

Technical Indicators

Market Signals
Indicator
DX
SUPN
Relative Strength Index (RSI) 38.37 45.67
Support Level $12.14 $43.43
Resistance Level $13.24 $46.79
Average True Range (ATR) 0.25 1.65
MACD -0.07 -0.16
Stochastic Oscillator 8.96 4.62

Price Performance

Historical Comparison
DX
SUPN

About DX Dynex Capital Inc.

Dynex Capital Inc is a real estate investment trust (REIT) focused on delivering dividends supported by long term returns from investments in mortgage assets backed by U.S. housing and commercial real estate. The Company is internally managed and mainly invests in residential and commercial mortgage-backed securities (RMBS and CMBS), which are Agency securities guaranteed by U.S. government-sponsored enterprises (GSEs). It manages interest rate, prepayment, spread, liquidity, and counterparty risks and operates through one reportable segment investing in MBS funded with repurchase agreements and equity.

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.

Share on Social Networks: